L929/A

This Adriamycin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line (ECACC catalogue number 85011425) to increasing concentrations of doxorubicin in-vitro. L929/A cells can be used in the development of novel anti-cancer treatments. Resistance can be circumvented by modulating agents such as verapamil and quinine. The parent cell line L929 was derived from normal subcutaneous areolar adipose tissue.

RPMI 1640 + 10% Fetal Bovine Serum (FBS) + 2mM L-Glutamine + 0.086 uM Doxorubicin hydrochloride.

Trypsinize with 0.05% Trypsin/EDTA and inoculate new cultures vessels at 1-2 x 10⁴ cells/cm². Cultures incubated in a humidified 5% CO₂/95% air incubator at 37^oC.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Cultures from PHE Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.